GlassScriptPhysician profile
Solomon Wesley Ross
NPI 1548499940
$5,119.96
in general payments reported to CMS, 2019-2025
24 companies · $1,497 in 2025
The $1,497 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $351 · 2021: $632 · 2022: $445 · 2023: $748 · 2024: $1,154 · 2025: $1,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,251 · Entertainment: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,251.43 |
| Entertainment | $148.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,114.21 | 2019-2025 | Clareon, Hydrus Microstent, Unity |
| Ani Pharmaceuticals, INC. | $518.45 | 2024 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $333.35 | 2019-2023 | |
| Nova Eye, INC. | $236.36 | 2024-2025 | |
| Sight Sciences, INC. | $215.55 | 2021-2025 | Omni Surgical System |
| Horizon Therapeutics Plc | $206.33 | 2023 | Tepezza |
| Dompe US, INC. | $160.07 | 2021-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $157.86 | 2020-2022 | |
| Aerie Pharmaceuticals, INC. | $148.40 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $137.47 | 2020-2025 | |
| Tarsus Pharmaceuticals, INC. | $126.75 | 2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $108.43 | 2021-2025 | Catalys System, Tecnis Simplicity |
| Amgen INC. | $108.37 | 2024-2025 | Tepezza |
| Glaukos Corporation | $91.67 | 2021-2025 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite |
| Bausch & Lomb Americas INC. | $88.17 | 2022-2024 | Vyzulta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $83.68 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Allergan, INC. | $79.34 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $78.30 | 2020-2021 | |
| Ocular Therapeutix, INC. | $24.56 | 2021-2024 | Dextenza |
| Rayner Intraocular Lenses Limited | $21.78 | 2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Abbvie INC. | $21.60 | 2023 | Xen Glaucoma Treatment System |
| Biotissue Holdings INC. | $20.92 | 2019-2020 | |
| Ivantis, INC | $20.19 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $18.15 | 2025 | Humphrey Hfa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Solomon Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.